



June 16, 2023
15:00 - 16:30 CET

Seminar

Empowering genomics with proteomics

Unlocking Novel Biomarkers with Olink® Technology. Protein by protein



Michael Förster, Ph.D
Scientific Director, Oncology
& Rare Disease, Olink Proteomics



Pasquale Cutolo
Field Application Scientist,
Olink Proteomics



Nicola Cirenei
Business Development,
Olink Proteomics

Olink Proteomics, a Swedish company with strong global presence, enables mid to high-plex protein biomarker discovery and development with unparalleled specificity and sensitivity. Olink's platform currently has the ability to robustly measure up to ~3,000 targets simultaneously. It's been widely adopted due to its scalability and actionability to help answer research questions aiming to elucidate signaling pathways in health and diseases, novel mechanisms of drug action or as a tool to identify actionable biomarker signatures with a prognostic/predictive value. With its expanding protein library, covering major biological pathways and >600 known drug targets, the Olink platform has been applied in the study of a wide variety of pathologies including rare congenital diseases.

Location:

Centro Cardiologico Monzino

Aula Magna

Via Carlo Parea 4 , 20138, Milano



Scan or click
the QR code to
register today

Agenda

15:00 - 15:10 | Welcome and Introduction to Olink Proteomics

15:10 - 15:40 | Proximity Extension Assay (PEA) Technology and Workflow Overview

15:40 - 16:15 | Empowering Genomics and Biomarker Discovery Through
Next Generation Proteomics & Case Studies Overview

16:15 - 16:30 | Q&A Session and Closing Remarks

© 2023 Olink Proteomics AB.

Olink products and services are For Research Use Only and not for Use in Diagnostic Procedures.

This document is not intended to convey any warranties or representations of any kind.

www.olink.com